<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39508462</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Final Results of the GRECCAR-6 Trial on Waiting Period Following Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer: 5 Years of Follow-up.</ArticleTitle><Pagination><StartPage>199</StartPage><EndPage>208</EndPage><MedlinePgn>199-208</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003477</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The potential oncological benefit of extending the waiting period between neoadjuvant radiochemotherapy and surgical resection for rectal cancer is debated.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the impact of prolonging this waiting period on the 5-year oncological prognosis and 2-year functional result of locally advanced rectal adenocarcinoma.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Phase III, multicenter, randomized, open-label, parallel-group, controlled trial.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Patients were enrolled from 24 colorectal centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with nonmetastatic mid or lower cT3/T4Nx or cTxN+ rectal adenocarcinoma who had received radiochemotherapy (45-50 Gy radiation dose with fluorouracil or capecitabine).</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Patients were randomly assigned to undergo total mesorectal excision either 7 weeks or 11 weeks after radiochemotherapy.</AbstractText><AbstractText Label="MAIN OUTCOMES MEASURES" NlmCategory="METHODS">Overall survival and disease-free survival at 5-year follow-up and low anterior resection syndrome score assessed after 2 years of follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 265 patients enrolled, 133 were randomized in the 7-week group and 132 in the 11-week group. Twelve patients were excluded because they did not undergo resection. Among 253 patients analyzed, 5-year overall survival was not different between the 2 groups (81.6% in the 7-week group vs 82.6% in the 11-week group, p = 0.827), and neither was the 5-year disease-free survival (70.4% in the 7-week group vs 69.5% in the 11-week group, p = 0.856). No difference was observed between the 2 groups for distant recurrence (27.4% in the 7-week group vs 25.7% in the 11-week group, p = 0.777) or local recurrence (8.4% in the 7-week group vs 10.2% in the 11-week group, p = 0.543). The low anterior resection syndrome score was similar between the 7-week (25.0; interquartile range, 15.0-34.0) and 11-week groups (23.0; interquartile range, 14.2-32.0; p = 0.743).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The response rate to the low anterior resection syndrome questionnaire was only 52%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Extending the waiting period between radiochemotherapy and resection from 7 to 11 weeks does not change the 5-year oncological prognosis in rectal cancer or the 2-year low anterior resection occurrence. See Video Abstract.</AbstractText><AbstractText Label="RESULTADOS FINALES DEL ENSAYO GRECCAR SOBRE EL PERODO DE ESPERA TRAS LA RADIOQUIMIOTERAPIA NEOADYUVANTE PARA EL CNCER DE RECTO LOCALMENTE AVANZADO AOS DE SEGUIMIENTO" NlmCategory="UNASSIGNED">ANTECEDENTES:Se debate el posible beneficio oncol&#xf3;gico de prolongar el periodo de espera entre la radioquimioterapia neoadyuvante y la resecci&#xf3;n quir&#xfa;rgica del c&#xe1;ncer de recto.OBJETIVO:Evaluar el impacto de la prolongaci&#xf3;n de este periodo de espera sobre el pron&#xf3;stico oncol&#xf3;gico a 5 a&#xf1;os y el resultado funcional a 2 a&#xf1;os del adenocarcinoma rectal localmente avanzado.DISE&#xd1;O:Ensayo controlado de fase III, multic&#xe9;ntrico, aleatorizado, abierto, de grupos paralelos.LUGAR:Se reclutaron pacientes de 24 centros colorrectales.PACIENTES:Pacientes con adenocarcinoma rectal de tercio medio o inferior, no metast&#xe1;sico cT3-4 o TxN+ que hab&#xed;an recibido radioquimioterapia (45 a 50 Gy con fluorouracilo o capecitabina).INTERVENCI&#xd3;N:Se asignaron aleatoriamente a los pacientes para ser sometidos a una escisi&#xf3;n mesorrectal total 7 semanas (W7) u 11 semanas (W11) despu&#xe9;s de la radioquimioterapia.MEDIDAS DE RESULTADOS PRINCIPALES:Supervivencia global y supervivencia libre de enfermedad a los 5 a&#xf1;os de seguimiento y puntuaci&#xf3;n del s&#xed;ndrome de resecci&#xf3;n anterior baja evaluada a los 2 a&#xf1;os de seguimiento.RESULTADOS:De los 265 pacientes reclutados, 133 fueron asignados aleatoriamente al grupo de 7 semanas y 132 al grupo de 11 semanas. Doce pacientes fueron excluidos porque no fueron sometidos a resecci&#xf3;n. Entre los 253 pacientes analizados, la supervivencia global a 5 a&#xf1;os no fue diferente entre los dos grupos (81,6% en el grupo de 7 semanas frente a 82,6% en el grupo de 11 semanas, p = 0,827), as&#xed; como para la supervivencia libre de enfermedad a 5 a&#xf1;os (70,4% en el grupo de 7 semanas frente a 69,5% en el grupo de 11 semanas, p = 0,856). No se observaron diferencias entre los dos grupos en cuanto a la recidiva a distancia (27,4% en el grupo de 7 semanas frente a 25,7% en el grupo de 11 semanas, p = 0,777) o la recidiva local (8,4% en el grupo de 7 semanas frente a 10,2% en el grupo de 11 semanas, p = 0,543). La puntuaci&#xf3;n del s&#xed;ndrome de resecci&#xf3;n anterior baja fue similar entre los grupos de 7 semanas (25,0 IQR [15,0-34,0]) y 11 semanas (23,0 IQR [14,2-32,0], p = 0,743).LIMITACIONES:La tasa de respuesta al cuestionario LARS fue s&#xf3;lo del 52%.CONCLUSIONES:Ampliar el periodo de espera entre radioquimioterapia y resecci&#xf3;n de 7 a 11 semanas no modifica el pron&#xf3;stico oncol&#xf3;gico a 5 a&#xf1;os en c&#xe1;ncer de recto ni la baja incidencia de resecci&#xf3;n anterior a 2 a&#xf1;os. (Traducci&#xf3;n-Dr Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Collard</LastName><ForeName>Maxime K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, F-75012, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mineur</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Oncology, Radiotherapy, Sainte-Camille Institut, Avignon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nekrouf</LastName><ForeName>C&#xe9;lia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Clinical Research Platform of the East of Paris (URC-CRC-CRB), Assistance Publique H&#xf4;pitaux de Paris, H&#xf4;pital St Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denost</LastName><ForeName>Quentin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Bordeaux Colorectal Institute, Clinique Tivoli-Ducos, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouanet</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Oncological Surgery, Val d'Aurelle Institut, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Chaisemartin</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Oncological Surgery, Paoli-Calmettes Institut, Marseille CHU, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merdrignac</LastName><ForeName>Aude</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Digestive Surgery, CHU, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafari</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oncological Surgery, Oscar Lambret Center, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotte</LastName><ForeName>Eddy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU Lyon-Sud, Pierre-B&#xe9;nite, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desrame</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastrology and Hepatology, Jean Mermoz Institut, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manceau</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Digestive and Hepatobiliary Surgery, CHU Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benoist</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Digestive and Oncological Surgery, CHU Bic&#xe8;tre, Le Kremlin-Bic&#xea;tre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buscail</LastName><ForeName>Etienne</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgery, CHU Purpan, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karoui</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Digestive, Oncological and General Surgery, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panis</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Colorectal Center, Groupe Hospitalier priv&#xe9; Ambroise Par&#xe9;-Hartmann, Neuilly-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piessen</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHRU, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saudemont</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery and Transplant Surgery, CHRU, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudhomme</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Digestive and Oncological Surgery, CHU Car&#xe9;meau, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peschaud</LastName><ForeName>Fr&#xe9;d&#xe9;rique</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU Ambroise-Par&#xe9;, Boulogne-Billancourt, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU Estaing, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loriau</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, St-Joseph Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuech</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duchalais</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU H&#xf4;tel-Dieu, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lupinacci</LastName><ForeName>Renato M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of General and Endocrine Surgery, Piti&#xe9; Salp&#xea;tri&#xe8;re Hospital, APHP, Sorbonne University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goasguen</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Croix Saint-Simon Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Tabassome</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Clinical Research Platform of the East of Paris (URC-CRC-CRB), Assistance Publique H&#xf4;pitaux de Paris, H&#xf4;pital St Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parc</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, F-75012, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefevre</LastName><ForeName>J&#xe9;r&#xe9;mie H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, F-75012, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>French Research Group of Rectal Cancer Surgery (GRECCAR)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PHRCN 2011, AOM 11314</GrantID><Agency>French Ministry of Health</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6804DJ8Z9U</RegistryNumber><NameOfSubstance UI="D000069287">Capecitabine</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069287" MajorTopicYN="N">Capecitabine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="Y">Chemoradiotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059186" MajorTopicYN="N">Chemoradiotherapy, Adjuvant</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>24</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>14</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>7</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39508462</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003477</ArticleId><ArticleId IdType="pii">00003453-990000000-00788</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926&#x2013;1933.</Citation></Reference><Reference><Citation>Lakkis Z, Manceau G, Bridoux V, et al.; French Research Group of Rectal Cancer Surgery (GRECCAR) and the French National Society of Coloproctology (SNFCP). Management of rectal cancer: the 2016 French guidelines. Colorectal Dis. 2017;19:115&#x2013;122.</Citation></Reference><Reference><Citation>van Gijn W, Marijnen CA, Nagtegaal ID, et al.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575&#x2013;582.</Citation></Reference><Reference><Citation>Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys. 2008;72:99&#x2013;107.</Citation></Reference><Reference><Citation>Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835&#x2013;844.</Citation></Reference><Reference><Citation>Collard MK, Rullier E, Panis Y, et al.; GRECCAR Group. Nonmetastatic ypt0 rectal cancer after neoadjuvant treatment and total mesorectal excision: lessons from a retrospective multicentric cohort of 383 patients. Surgery. 2022;171:1193&#x2013;1199.</Citation></Reference><Reference><Citation>Loria A, Tejani MA, Temple LK, et al. Practice patterns for organ preservation in US patients with rectal cancer, 2006-2020. JAMA Oncol. 2024;10:79&#x2013;86.</Citation></Reference><Reference><Citation>Habr-Gama A, S&#xe3;o Juli&#xe3;o GP, Fernandez LM, et al. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think! Dis Colon Rectum. 2019;62:802&#x2013;808.</Citation></Reference><Reference><Citation>Ryan EJ, O&#x2019;Sullivan DP, Kelly ME, et al. Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer. Br J Surg. 2019;106:1298&#x2013;1310.</Citation></Reference><Reference><Citation>Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016;263:458&#x2013;464.</Citation></Reference><Reference><Citation>Lefevre JH, Rousseau A, Svrcek M, Parc Y, Simon T, Tiret E; French Research Group of Rectal Cancer Surgery (GRECCAR). A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design. BMC Cancer. 2013;13:417.</Citation></Reference><Reference><Citation>Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34:3773&#x2013;3780.</Citation></Reference><Reference><Citation>Yu M, Wang DC, Li S, Huang LY, Wei J. Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses. Int J Colorectal Dis. 2022;37:855&#x2013;868.</Citation></Reference><Reference><Citation>Cheng YK, Qin QY, Huang XY, et al. Effect of interval between preoperative radiotherapy and surgery on clinical outcome and radiation proctitis in rectal cancer from FOWARC trial. Cancer Med. 2020;9:912&#x2013;919.</Citation></Reference><Reference><Citation>Lef&#xe8;vre JH, Mineur L, Cachanado M, et al.; The French Research Group of Rectal Cancer Surgery (GRECCAR). Does a longer waiting period after neoadjuvant radio-chemotherapy improve the oncological prognosis of rectal cancer? Three years&#x2019; follow-up results of the greccar-6 randomized multicenter trial. Ann Surg. 2019;270:747&#x2013;754.</Citation></Reference><Reference><Citation>Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg. 2012;255:922&#x2013;928.</Citation></Reference><Reference><Citation>Mihmanli M, Kabul G&#xfc;rbulak E, Akg&#xfc;n IE, et al. Delaying surgery after neoadjuvant chemoradiotherapy improves prognosis of rectal cancer. World J Gastrointest Oncol. 2016;8:695&#x2013;706.</Citation></Reference><Reference><Citation>Maliske S, Chau J, Ginader T, et al. Timing of surgery following neoadjuvant chemoradiation in rectal cancer: a retrospective analysis from an academic medical center. J Gastrointest Oncol. 2019;10:597&#x2013;604.</Citation></Reference><Reference><Citation>Akgun E, Caliskan C, Bozbiyik O, et al. Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2018;105:1417&#x2013;1425.</Citation></Reference><Reference><Citation>Akgun E, Caliskan C, Bozbiyik O, et al. Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial. BJS Open. 2022;6:zrac107.</Citation></Reference><Reference><Citation>Nougaret S, Castan F, de Forges H, et al.; GRECCAR Study Group. Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial. Br J Surg. 2019;106:1530&#x2013;1541.</Citation></Reference><Reference><Citation>Niu S, Chen Y, Peng F, et al. The role of MRI after neochemoradiotherapy in predicting pathological tumor regression grade and clinical outcome in patients with locally advanced rectal adenocarcinoma. Front Oncol. 2023;13:1118518.</Citation></Reference><Reference><Citation>Deidda S, Elmore U, Rosati R, et al. Association of delayed surgery with oncologic long-term outcomes in patients with locally advanced rectal cancer not responding to preoperative chemoradiation. JAMA Surg. 2021;156:1141&#x2013;1149.</Citation></Reference><Reference><Citation>Jang JK, Choi SH, Park SH, et al. MR tumor regression grade for pathological complete response in rectal cancer post neoadjuvant chemoradiotherapy: a systematic review and meta-analysis for accuracy. Eur Radiol. 2020;30:2312&#x2013;2323.</Citation></Reference><Reference><Citation>He S, Zhang J, Wang R, et al. Impact of long-course neoadjuvant radiation on postoperative low anterior resection syndrome and stoma status in rectal cancer: long-term functional follow-up of a randomized clinical trial. BJS Open. 2022;6:zrac127.</Citation></Reference><Reference><Citation>Dijkstra EA, Nilsson PJ, Hospers GAP, et al.; Collaborative Investigators. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg. 2023;278:e766&#x2013;e772.</Citation></Reference><Reference><Citation>Meyer VM, Meuzelaar RR, Schoenaker Y, et al. Delayed surgery after neoadjuvant treatment for rectal cancer does not lead to impaired quality of life, worry for cancer, or regret. Cancers (Basel). 2021;13:742.</Citation></Reference><Reference><Citation>Varghese C, Wells CI, O&#x2019;Grady G, Christensen P, Bissett IP, Keane C; on behalf of the Longitudinal LARS Group. The longitudinal course of low-anterior resection syndrome: an individual patient meta-analysis. Ann Surg. 2022;276:46&#x2013;54.</Citation></Reference><Reference><Citation>Conroy T, Bosset JF, Etienne PL, et al.; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702&#x2013;715.</Citation></Reference><Reference><Citation>Schrag D, Shi Q, Weiser MR, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med. 2023;389:322&#x2013;334.</Citation></Reference><Reference><Citation>Lefevre J, Collard M, Mineur L, et al. Finals results of the GRECCAR-6 trial on waiting period following neo-adjuvant radio-chemotherapy for advanced rectal cancer: 5 years follow-up [ASCRS abstract SS05]. Dis Colon Rectum. 2024;67:e435&#x2013;e436.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39432728</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>The Impact of a Modular Robotic Total Mesorectal Excision Training Program on Perioperative and Oncological Outcomes in Robotic Rectal Cancer Surgery.</ArticleTitle><Pagination><StartPage>1485</StartPage><EndPage>1494</EndPage><MedlinePgn>1485-1494</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003370</ELocationID><Abstract><AbstractText Label="BACKGROUND">Structured training programs for robotic colorectal surgery are limited, and there are concerns about surgical outcomes and operating times.</AbstractText><AbstractText Label="OBJECTIVE">To compare perioperative and oncological outcomes of robotic total mesorectal excision for rectal cancer performed by expert consultants and surgical trainees in a modular surgical training program.</AbstractText><AbstractText Label="DESIGN">Retrospective cohort study.</AbstractText><AbstractText Label="SETTINGS">Conducted at a colorectal training referral center for robotic surgery.</AbstractText><AbstractText Label="PATIENTS">Consecutive robotic total mesorectal excision cases between May 2013 and December 2017 were evaluated retrospectively from a prospectively maintained institutional database and divided into 2 groups: group I comprised expert surgeons and group II comprised supervised trainees. Robotic total mesorectal excision training modules (5 modules) were performed stepwise with increasing complexity. Patients' demographic, perioperative, and oncological data were collected.</AbstractText><AbstractText Label="INTERVENTIONS">Modular robotic training.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Comparable R0 resection rate, lymph node harvest, and oncological outcomes between experts and trainees, suggesting good quality in oncological resection.</AbstractText><AbstractText Label="RESULTS">A total of 177 robotic total mesorectal excision resections were performed (group I: n = 80, group II: n = 97). Four trainees completed 37.5 modules each. Patients' age, sex, and BMI were similar between groups. Group II had a higher ASA III score (6.3% vs 25.8%, p = 0.002). Clinical TNM and neoadjuvant chemoradiotherapy rates were similar. Group II had a longer operative time (225 [197.5-297.5] vs 250 [230-300] minutes, p = 0.004). No conversion occurred. There were no differences in intra- or postoperative outcomes between groups. The rate of R0 resection and the number of harvested lymph nodes were also similar between groups. The median follow-up was 75 (64.0-81.7) and 47 (38.0-55.0) months, respectively. Local and distant recurrence rates, 5-year overall survival (81.1% group I vs 81.3% group II, p = 0.832), and 5-year disease-free survival (79.7% group I vs 80.7% group II, p = 0.725) were similar between groups.</AbstractText><AbstractText Label="LIMITATIONS">The groups operated in 2 consecutive periods.</AbstractText><AbstractText Label="CONCLUSIONS">The robotic total mesorectal excision modular surgical training program maximizes training experience without significantly affecting the perioperative and oncological outcomes of patients with rectal cancer. See Video Abstract.</AbstractText><AbstractText Label="EL IMPACTO DEL PROGRAMA MODULAR DE ENTRENAMIENTO EN ESCISIN MESORRECTAL TOTAL ROBTICA EN LOS RESULTADOS PERIOPERATORIOS Y ONCOLGICOS EN LA CIRUGA ROBTICA DEL CNCER DE RECTO">ANTECEDENTES:Los programas de entrenamiento estructurados para la cirug&#xed;a colorrectal rob&#xf3;tica est&#xe1;n limitados debido a preocupaciones sobre los resultados quir&#xfa;rgicos y los tiempos de operaci&#xf3;n.OBJETIVO:Comparar los resultados perioperatorios y oncol&#xf3;gicos de la escisi&#xf3;n mesorrectal total rob&#xf3;tica para el c&#xe1;ncer de recto realizada por consultores expertos y aprendices de cirug&#xed;a en un programa modular de entrenamiento quir&#xfa;rgica.DISE&#xd1;O:Estudio de cohorte retrospectivo.AJUSTES:Realizado en un centro de referencia de entrenamiento colorrectal para cirug&#xed;a rob&#xf3;tica.PACIENTES:Se evaluaron retrospectivamente casos consecutivos de escisi&#xf3;n mesorrectal total rob&#xf3;tica entre mayo de 2013 y diciembre de 2017 a partir de una base de datos institucional mantenida prospectivamente y se dividieron en dos grupos: Grupo I: cirujanos expertos; Grupo II: aprendices supervisados. Los m&#xf3;dulos de entrenamiento rob&#xf3;tico de escisi&#xf3;n mesorrectal total (cinco m&#xf3;dulos) se realizaron paso a paso con complejidad creciente. Se recogieron datos demogr&#xe1;ficos, perioperatorios y oncol&#xf3;gicos.INTERVENCIONES:Entrenamiento modular en rob&#xf3;tica.PRINCIPALES MEDIDAS DE RESULTADO:Tasa de resecci&#xf3;n R0 comparable, extracci&#xf3;n de ganglios linf&#xe1;ticos y resultados oncol&#xf3;gicos entre expertos y aprendices que sugieren buena calidad en la resecci&#xf3;n oncol&#xf3;gica.RESULTADOS:Se realizaron un total de 177 resecciones por escisi&#xf3;n mesorrectal total rob&#xf3;tica (Grupo I: n = 80, Grupo II: n = 97). Cuatro alumnos completaron 37,5 m&#xf3;dulos cada uno. La edad, el sexo y el IMC fueron similares entre los grupos. El grupo II tuvo una puntuaci&#xf3;n m&#xe1;s alta de la Sociedad Americana de Anestesi&#xf3;logos III (6,3% frente a 25,8%, p = 0,002). Las tasas cl&#xed;nicas de TNM y quimiorradioterapia neoadyuvante fueron similares. El grupo II tuvo mayor tiempo operatorio (225 (197,5-297,5) vs 250 (230-300) minutos, p = 0,004). No se produjo ninguna conversi&#xf3;n. No hubo diferencias en los resultados intra o posoperatorios entre los grupos. La tasa de resecci&#xf3;n R0 y el n&#xfa;mero de ganglios linf&#xe1;ticos extra&#xed;dos tambi&#xe9;n fueron similares entre los grupos. La mediana de seguimiento fue de 75 (64,0-81,7) y 47 (38,0-55,0) meses, respectivamente. Tasas de recurrencia local y a distancia, supervivencia general a 5 a&#xf1;os (81,1% Grupo I vs. 81,3% Grupo II, p = 0,832) y supervivencia libre de enfermedad a 5 a&#xf1;os (79,7% Grupo I vs. 80,7% Grupo II, p = 0,725) fueron similares entre los grupos.LIMITACIONES:Los grupos operaron en dos per&#xed;odos consecutivos.CONCLUSIONES:El programa de entrenamiento quir&#xfa;rgico modular para la escisi&#xf3;n mesorrectal total rob&#xf3;tica maximiza la experiencia de capacitaci&#xf3;n sin afectar significativamente los resultados perioperatorios y oncol&#xf3;gicos de los pacientes con c&#xe1;ncer de recto. (Traducci&#xf3;n-Dr. Aurian Garcia Gonzalez).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stefan</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1542-3332</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piozzi</LastName><ForeName>Guglielmo Niccol&#xf2;</ForeName><Initials>GN</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tejedor</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8648-7697</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Christopher C L</ForeName><Initials>CCL</Initials><Identifier Source="ORCID">0000-0002-2862-0725</Identifier><AffiliationInfo><Affiliation>Colorectal Department, East and North Hertfordshire NHS Trust, Lister Hospital, Stevenage, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Anwar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1806-8970</Identifier><AffiliationInfo><Affiliation>Colorectal Department, Basildon and Thurrock University Hospital, Basildon, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Nasir Z</ForeName><Initials>NZ</Initials><Identifier Source="ORCID">0000-0001-8085-4644</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naqvi</LastName><ForeName>Syed A H</ForeName><Initials>SAH</Initials><Identifier Source="ORCID">0000-0003-3516-4200</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heald</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Pelican Cancer Foundation, Basingstoke, Hampshire, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Jim S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-3031-4495</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Science and Health, University of Portsmouth, Portsmouth, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065287" MajorTopicYN="Y">Robotic Surgical Procedures</DescriptorName><QualifierName UI="Q000193" MajorTopicYN="N">education</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061646" MajorTopicYN="N">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000193" MajorTopicYN="N">education</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002983" MajorTopicYN="N">Clinical Competence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>22</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>14</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39432728</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003370</ArticleId><ArticleId IdType="pii">00003453-202411000-00017</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>Khan JS, Banerjee AK, Kim SH, Rockall TA, Jayne DG. Robotic rectal surgery has advantages over laparoscopic surgery in selected patients and centres. Colorectal Dis. 2018;20:845&#x2013;853.</Citation></Reference><Reference><Citation>Chouhan H, Shin J, Kim SH. Is robotic rectal resection the preferred option for resectable cancer? . Mini-invasive Surg. 2018;2:18.</Citation></Reference><Reference><Citation>Kim JS, Piozzi GN, Kwak JM, et al. Quality of laparoscopic camera navigation in robot-assisted versus conventional laparoscopic surgery for rectal cancer: an analysis of surgical videos through a video processing computer software. Int J Med Robot. 2022;18:e2393.</Citation></Reference><Reference><Citation>Piozzi GN, Kim SH. Robotic intersphincteric resection for low rectal cancer: technical controversies and a systematic review on the perioperative, oncological, and functional outcomes. Ann Coloproctol. 2021;37:351&#x2013;367.</Citation></Reference><Reference><Citation>Aliyev V, Goksel S, Bakir B, Guven K, Asoglu O. Sphincter-saving robotic total mesorectal excision provides better mesorectal specimen and good oncological local control compared with laparoscopic total mesorectal excision in male patients with mid-low rectal cancer. Surg Technol Int. 2021;38:160&#x2013;166.</Citation></Reference><Reference><Citation>Piozzi GN, Rusli SM, Lee TH, et al. Robotic approach may be associated with a lower risk of lung metastases compared to laparoscopic approach for mid-low rectal cancer after neoadjuvant chemoradiotherapy: a multivariate analysis on long-term recurrence patterns. Int J Colorectal Dis. 2022;37:2085&#x2013;2098.</Citation></Reference><Reference><Citation>Harji D, Houston F, Burke J, et al. The current status of robotic colorectal surgery training programmes. J Robot Surg. 2023;17:251&#x2013;263.</Citation></Reference><Reference><Citation>Mikhail E, Salemi JL, Hart S, Imudia AN. Comparing single and dual console systems in the robotic surgical training of graduating OB/GYN residents in the United States. Minim Invasive Surg. 2016;2016:5190152.</Citation></Reference><Reference><Citation>Bolger JC, Broe MP, Zarog MA, et al. Initial experience with a dual-console robotic-assisted platform for training in colorectal surgery. Tech Coloproctol. 2017;21:721&#x2013;727.</Citation></Reference><Reference><Citation>Hanna GB, Mackenzie H, Miskovic D, et al.; on behalf of Lapco program. Laparoscopic Colorectal Surgery Outcomes Improved After National Training Program (LAPCO) for specialists in England. Ann Surg. 2022;275:1149&#x2013;1155.</Citation></Reference><Reference><Citation>Tarr ME, Rivard C, Petzel AE, et al. Robotic objective structured assessment of technical skills: a randomized multicenter dry laboratory training pilot study. Female Pelvic Med Reconstr Surg. 2014;20:228&#x2013;236.</Citation></Reference><Reference><Citation>Korets R, Mues AC, Graversen JA, et al. Validating the use of the Mimic dV-trainer for robotic surgery skill acquisition among urology residents. Urology. 2011;78:1326&#x2013;1330.</Citation></Reference><Reference><Citation>Pernar LIM, Robertson FC, Tavakkoli A, Sheu EG, Brooks DC, Smink DS. An appraisal of the learning curve in robotic general surgery. Surg Endosc. 2017;31:4583&#x2013;4596.</Citation></Reference><Reference><Citation>Smith R, Patel V, Satava R. Fundamentals of robotic surgery: a course of basic robotic surgery skills based upon a 14-society consensus template of outcomes measures and curriculum development. Int J Med Robot. 2014;10:379&#x2013;384.</Citation></Reference><Reference><Citation>Petz W, Spinoglio G, Choi GS, et al. Structured training and competence assessment in colorectal robotic surgery. Results of a consensus experts round table. Int J Med Robot. 2016;12:634&#x2013;641.</Citation></Reference><Reference><Citation>Han YE, Park BJ, Sung DJ, et al. How to accurately measure the distance from the anal verge to rectal cancer on MRI: a prospective study using anal verge markers. Abdom Radiol (NY). 2021;46:449&#x2013;458.</Citation></Reference><Reference><Citation>Weiser MR. AJCC 8th edition: colorectal cancer. Ann Surg Oncol. 2018;25:1454&#x2013;1455.</Citation></Reference><Reference><Citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205&#x2013;213.</Citation></Reference><Reference><Citation>Rahbari NN, Weitz J, Hohenberger W, et al. Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery. 2010;147:339&#x2013;351.</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344&#x2013;349.</Citation></Reference><Reference><Citation>Mykoniatis I, Siddiqi NN, Khan JS. Robotic low anterior resection. Dis Colon Rectum. 2021;64:e32&#x2013;e33.</Citation></Reference><Reference><Citation>Tejedor P, Sagias F, Nock D, et al. Advantages of using a robotic stapler in rectal cancer surgery. J Robot Surg. 2020;14:365&#x2013;370.</Citation></Reference><Reference><Citation>Waqas A, Mykoniatis I, Sidiqi N, et al. Early experience of undertaking robotic assisted total mesorectal excision in rectal resections, avoiding a diverting stoma: key eHancement of the anastomosis for no stoma technique&#x2014;a case series. Surg Innov. 2023;30:158&#x2013;165.</Citation></Reference><Reference><Citation>Ahmed J, Nasir M, Flashman K, Khan J, Parvaiz A. Totally robotic rectal resection: an experience of the first 100 consecutive cases. Int J Colorectal Dis. 2016;31:869&#x2013;876.</Citation></Reference><Reference><Citation>Ahmed J, Siddiqi N, Khan L, Kuzu A, Parvaiz A. Standardized technique for single-docking robotic rectal surgery. Colorectal Dis. 2016;18:O380&#x2013;O384.</Citation></Reference><Reference><Citation>Stolzenburg JU, Schwaibold H, Bhanot SM, et al. Modular surgical training for endoscopic extraperitoneal radical prostatectomy. BJU Int. 2005;96:1022&#x2013;1027.</Citation></Reference><Reference><Citation>Schachner T, Bonaros N, Wiedemann D, et al. Training surgeons to perform robotically assisted totally endoscopic coronary surgery. Ann Thorac Surg. 2009;88:523&#x2013;527.</Citation></Reference><Reference><Citation>Gallagher AG, Ritter EM, Champion H, et al. Virtual reality simulation for the operating room: proficiency-based training as a paradigm shift in surgical skills training. Ann Surg. 2005;241:364&#x2013;372.</Citation></Reference><Reference><Citation>Gallagher AG. Metric-based simulation training to proficiency in medical education: what it is and how to do it. Ulster Med J. 2012;81:107&#x2013;113.</Citation></Reference><Reference><Citation>Guend H, Widmar M, Patel S, et al. Developing a robotic colorectal cancer surgery program: understanding institutional and individual learning curves. Surg Endosc. 2017;31:2820&#x2013;2828.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38064243</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Longitudinal Analysis of Local Recurrence and Survival After Transanal Abdominal Transanal Radical Proctosigmoidectomy for Low Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy.</ArticleTitle><Pagination><StartPage>377</StartPage><EndPage>386</EndPage><MedlinePgn>377-386</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003146</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The transanal abdominal transanal radical proctosigmoidectomy was developed in 1984 as a sphincter preservation surgery in patients with low rectal cancers after preoperative radiation therapy. While serving as a catalyst for disruptive sphincter preservation surgery, it continues to be used and evolve. With the controversy over safety and local recurrence in other sphincter-preserving surgery, review of transanal abdominal transanal radical proctosigmoidectomy long-term oncologic outcomes is warranted.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess local recurrence and survival after transanal abdominal transanal radical proctosigmoidectomy after neoadjuvant chemoradiation therapy.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cohort study of a prospectively maintained database.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Tertiary rectal cancer referral center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with low adenocarcinoma (&#x2264;5&#x2009;cm anorectal ring) receiving neoadjuvant chemoradiation therapy and then transanal abdominal transanal radical proctosigmoidectomy for curative resection between 1998 and 2021.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Local recurrence rates and overall survival rates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 255 included patients, 67.8% were men (n = 173); the mean age was 58.7 years (SD 11.5) and the mean BMI was 27.1 (SD 5.4), with 50.2% (n = 128) having ASA class II and 49.8% (n = 127) having ASA class III/IV. The mean tumor size was 4.8&#x2009;cm (SD 1.9), the majority of patients had clinical T3 disease (81.8%; n = 184), and 52.1% had nodal disease (n = 100). The median radiation dose was 5400 cGy, with 73.7% (n = 149) achieving good response and 90.2% (n = 230) receiving minimally invasive surgery. The complete total mesorectal excision rate was 94.3%, and 100% of patients (n = 255) had negative distal margins. The mean number of examined lymph nodes were 13.9 (SD 10.7). After a median follow-up of 55.4 months, 5.1% of patients (n = 13) developed local recurrence at a median time of 29.6 months. The 5-year overall survival was 84.1% (95% CI, 78.8-89.4).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective review with risk of bias and lack of generalizability.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this longitudinal study, the transanal abdominal transanal radical proctosigmoidectomy demonstrated excellent long-term locoregional control and survival in very low rectal cancers. The superior transanal abdominal transanal radical proctosigmoidectomy outcomes are durable over time, warranting expansion of the sphincter-preserving surgery technique. See Video Abstract .</AbstractText><AbstractText Label="ANLISIS LONGITUDINAL DE LA RECURRENCIA LOCAL Y LA SUPERVIVENCIA DESPUS DE LA PROCTOSIGMOIDECTOMA RADICAL TRANSANAL ABDOMINAL TATA PARA EL CNCER DE RECTO BAJO TRATADO CON QUIMIORRADIACIN NEOADYUVANTE" NlmCategory="UNASSIGNED">ANTECEDENTES:La proctosigmoidectom&#xed;a radical transanal abdominal se desarroll&#xf3; en 1984 como una cirug&#xed;a de preservaci&#xf3;n del esf&#xed;nter en c&#xe1;nceres de recto bajo despu&#xe9;s de la radiaci&#xf3;n preoperatoria. Si bien sirve como catalizador para la cirug&#xed;a disruptiva de preservaci&#xf3;n del esf&#xed;nter, contin&#xfa;a utiliz&#xe1;ndose y evolucionando. Con la controversia sobre la seguridad y la recurrencia local en otras cirug&#xed;as que preservan el esf&#xed;nter, se justifica la revisi&#xf3;n de los resultados oncol&#xf3;gicos a largo plazo de la proctosigmoidectom&#xed;a radical transanal abdominal.OBJETIVO:Evaluar localmente despu&#xe9;s de Proctosigmoidectom&#xed;a Radical Transanal Abdominal Transanal despu&#xe9;s de quimiorradiaci&#xf3;n neoadyuvante.DISE&#xd1;O:Estudio de cohorte retrospectivo de una base de datos mantenida de forma prospectiva.AJUSTES:Centro terciario de referencia para el c&#xe1;ncer de recto.PACIENTES:Adenocarcinoma bajo (=/&lt;anillo anorrectal [ARR] de 5&#x2009;cm) que recibi&#xf3; quimiorradiaci&#xf3;n neoadyuvante y luego proctosigmoidectom&#xed;a radical transanal abdominal transanal para resecci&#xf3;n curativa entre 1998-2021.PRINCIPALES MEDIDAS DE RESULTADO:Tasas de recurrencia local y tasas de supervivencia general.RESULTADOS:De los 255 incluidos, el 67,8% eran varones (n = 173), con una edad media de 58,7 a&#xf1;os (desviaci&#xf3;n est&#xe1;ndar 11,5), con un &#xed;ndice de masa corporal medio de 27,1&#x2009;kg/m2 (desviaci&#xf3;n est&#xe1;ndar, 5,4) y el 50,2% (n = 128) estadounidenses. Sociedad de Anestesiolog&#xed;a II. El tama&#xf1;o medio del tumor fue de 4,8&#x2009;cm (desviaci&#xf3;n est&#xe1;ndar 1,9), la mayor&#xed;a cl&#xed;nica T3 (81,8%, n = 184) y el 52,1% ten&#xed;a enfermedad ganglionar (n = 100). La dosis de radiaci&#xf3;n mediana fue de 5400cGy, y el 73,7% (n = 149) logr&#xf3; una buena respuesta. El 90,2% (n = 230) se someti&#xf3; a cirug&#xed;a m&#xed;nimamente invasiva. La tasa de escisi&#xf3;n mesorrectal total completa fue del 94,3% (n = 83/87) y el 100% (n = 255) tuvo m&#xe1;rgenes distales negativos. La media de ganglios linf&#xe1;ticos examinados fue de 13,9 (desviaci&#xf3;n est&#xe1;ndar, 10,7). Despu&#xe9;s de una mediana de seguimiento de 55,4 meses, el 5,1% (n = 13) de los pacientes desarrollaron recurrencia local, en una mediana de tiempo de 29,6 meses. La supervivencia global a 5 a&#xf1;os fue del 84,1% (IC 95%: 78,8-89,4).LIMITACIONES:Revisi&#xf3;n retrospectiva con riesgo de sesgo y falta de generalizaci&#xf3;n.CONCLUSIONES:En este estudio longitudinal, la proctosigmoidectom&#xed;a radical transanal abdominal demostr&#xf3; un excelente control locorregional a largo plazo y supervivencia en c&#xe1;nceres de recto muy bajos. Los resultados superiores de la proctosigmoidectom&#xed;a radical transanal abdominal son duraderos en el tiempo, lo que justifica la expansi&#xf3;n de la t&#xe9;cnica quir&#xfa;rgica de preservaci&#xf3;n del esf&#xed;nter. (Traducci&#xf3;n-Dr. Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>John H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-5977-0603</Identifier><AffiliationInfo><Affiliation>Lankenau Medical Center, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reif de Paula</LastName><ForeName>Thais</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2569-5019</Identifier></Author><Author ValidYN="Y"><LastName>Saidi</LastName><ForeName>Hela</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ikner</LastName><ForeName>Taylor P</ForeName><Initials>TP</Initials></Author><Author ValidYN="Y"><LastName>Schoonyoung</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>Gerald</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Deborah S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0002-8645-6206</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Financial Disclosure: Dr. Marks reports speaker&#x2019;s bureau and consultancy fees on behalf of Intuitive Surgical, Medtronic, Stryker, 270 Surgical, Vascular Technology, and Virtual Incision outside of the current work. Dr. Schoonyoung reports consultancy fees on behalf of Virtual Incision outside of the current work. Dr. Keller reports compensation for faculty and speaker services from Medtronic outside of the current work. The other authors have no relevant conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38064243</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003146</ArticleId><ArticleId IdType="pii">00003453-202403000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Graney MJ, Graney CM. Colorectal surgery from antiguity to the modern era. Dis Colon Rectum. 1980;23:432&#x2013;441.</Citation></Reference><Reference><Citation>Janeway H. Treatment of cancer, particularly of the tongue, tonsil and rectum, by buried emanation. AJR Am J Roentgenol. 1920;7:92&#x2013;101.</Citation></Reference><Reference><Citation>Binkley GE. Radiation in the treatment of rectal cancer. Ann Surg. 1929;90:1000&#x2013;1014.</Citation></Reference><Reference><Citation>Miles WE. The present position of the radical abdomino-perineal operation for cancer of the rectum in regard to mortality and post-operative recurrence. Proc R Soc Med. 1931;24:989&#x2013;991.</Citation></Reference><Reference><Citation>Heald RJ, Smedh RK, Kald A, Sexton R, Moran BJ. Abdominoperineal excision of the rectum&#x2014;an endangered operation Norman Nigro Lectureship. Dis Colon Rectum. 1997;40:747&#x2013;751.</Citation></Reference><Reference><Citation>How P, Shihab O, Tekkis P, et al. A systematic review of cancer related patient outcomes after anterior resection and abdominoperineal excision for rectal cancer in the total mesorectal excision era. Surg Oncol. 2011;20:e149&#x2013;e155.</Citation></Reference><Reference><Citation>Marks G, Mohiuddin M, Goldstein SD. Sphincter preservation for cancer of the distal rectum using high dose preoperative radiation. Int J Radiat Oncol Biol Phys. 1988;15:1065&#x2013;1068.</Citation></Reference><Reference><Citation>Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1:1479&#x2013;1482.</Citation></Reference><Reference><Citation>Kapiteijn E, Marijnen CA, Nagtegaal ID, et al.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638&#x2013;646.</Citation></Reference><Reference><Citation>Bosset JF, Collette L, Calais G, et al.; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114&#x2013;1123.</Citation></Reference><Reference><Citation>Sauer R, Becker H, Hohenberger W, et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731&#x2013;1740.</Citation></Reference><Reference><Citation>Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926&#x2013;1933.</Citation></Reference><Reference><Citation>Papaccio F, Rosell&#xf3; S, Huerta M, et al. Neoadjuvant chemotherapy in locally advanced rectal cancer. Cancers (Basel). 2020;12:3611.</Citation></Reference><Reference><Citation>Gazet JC. Parks&#x2019; coloanal pull-through anastomosis for severe, complicated radiation proctitis. Dis Colon Rectum. 1985;28:110&#x2013;114.</Citation></Reference><Reference><Citation>Kirwan WO, Turnbull RB. The Turnbull-Cutait pullthrough procedure for certain cancers of the rectum and Hirschsprung disease. Int Adv Surg Oncol. 1981;4:173&#x2013;187.</Citation></Reference><Reference><Citation>Marks GJ, Marks JH, Mohiuddin M, Brady L. Radical Sphincter preservation surgery with coloanal anastomosis following high-dose external irradiation for the very low lying rectal cancer. Recent Results Cancer Res. 1998;146:161&#x2013;174.</Citation></Reference><Reference><Citation>Marks JH, Salem JF, Valsdottir EB, Yarandi SS, Marks GJ. Quality of life and functional outcome after transanal abdominal transanal proctectomy for low rectal cancer. Dis Colon Rectum. 2017;60:258&#x2013;265.</Citation></Reference><Reference><Citation>Sylla P, Rattner DW, Delgado S, Lacy AM. NOTES transanal rectal cancer resection using transanal endoscopic microsurgery and laparoscopic assistance. Surg Endosc. 2010;24:1205&#x2013;1210.</Citation></Reference><Reference><Citation>Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711&#x2013;717; discussion 717.</Citation></Reference><Reference><Citation>Fearnhead NS, Acheson AG, Brown SR, et al.; Association of Coloproctology of Great Britain, Ireland (ACPGBI) Executive, Getting It Right First Time (GIRFT). The ACPGBI recommends pause for reflection on transanal total mesorectal excision. Colorectal Dis. 2020;22:745&#x2013;748.</Citation></Reference><Reference><Citation>van Oostendorp SE, Belgers HJ, Bootsma BT, et al. Locoregional recurrences after transanal total mesorectal excision of rectal cancer during implementation. Br J Surg. 2020;107:1211&#x2013;1220.</Citation></Reference><Reference><Citation>Wasmuth HH, Faerden AE, Myklebust TA, et al.; Norwegian TaTME Collaborative Group, on behalf of the Norwegian Colorectal Cancer Group. Transanal total mesorectal excision for rectal cancer has been suspended in Norway. Br J Surg. 2020;107:121&#x2013;130.</Citation></Reference><Reference><Citation>Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma clinicopathologic correlations. Cancer. 1994;73:2680&#x2013;2686.</Citation></Reference><Reference><Citation>Marks J, Nassif G, Schoonyoung H, et al. Sphincter-sparing surgery for adenocarcinoma of the distal 3&#x2009;cm of the true rectum: results after neoadjuvant therapy and minimally invasive radical surgery or local excision. Surg Endosc. 2013;27:4469&#x2013;4477.</Citation></Reference><Reference><Citation>Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187&#x2013;196.</Citation></Reference><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Clinical Practice Guidelines in Oncology&#x2013;rectal cancer&#x2013;version 6.2023&#x2014;November 16, 2023. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf . Accessed December 11, 2023.</Citation></Reference><Reference><Citation>Collaborative TBTME. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg. 2013;100:1009&#x2013;1014.</Citation></Reference><Reference><Citation>Zwart WH, Hotca A, Hospers GAP, Goodman KA, Garcia-Aguilar J. The multimodal management of locally advanced rectal cancer: making sense of the new data. Am Soc Clin Oncol Educ Book. 2022;42:1&#x2013;14.</Citation></Reference><Reference><Citation>Manfredi S, Benhamiche AM, Meny B, Cheynel N, Rat P, Faivre J. Population-based study of factors influencing occurrence and prognosis of local recurrence after surgery for rectal cancer. Br J Surg. 2001;88:1221&#x2013;1227.</Citation></Reference><Reference><Citation>Silberfein EJ, Kattepogu KM, Hu CY, et al. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol. 2010;17:2863&#x2013;2869.</Citation></Reference><Reference><Citation>Wasmuth HH, Gachabayov M, Bokey L, et al. Statistical, clinical, methodological evaluation of local recurrence following transanal total mesorectal excision for rectal cancer: a systematic review. Dis Colon Rectum. 2021;64:899&#x2013;914.</Citation></Reference><Reference><Citation>Roodbeen SX, Penna M, van Dieren S, et al.; International TaTME Registry Collaborative. Local recurrence and disease-free survival after transanal total mesorectal excision: results from the International TaTME Registry. J Natl Compr Canc Netw. 2021;19:1232&#x2013;1240.</Citation></Reference><Reference><Citation>Van Oostendorp SE, Belgers HJE, Hol JC, et al. The learning curve of transanal total mesorectal excision for rectal cancer is associated with local recurrence: results from a multicentre external audit. Colorectal Dis. 2021;23:2020&#x2013;2029.</Citation></Reference><Reference><Citation>Marks G, Mohiuddin M, Masoni L. The reality of radical sphincter preservation surgery for cancer of the distal 3&#x2009;cm of rectum following high-dose radiation. Int J Radiat Oncol Biol Phys. 1993;27:779&#x2013;783.</Citation></Reference><Reference><Citation>G&#xe9;rard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620&#x2013;4625.</Citation></Reference><Reference><Citation>Battersby NJ, How P, Moran B, et al.; MERCURY II Study Group. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg. 2016;263:751&#x2013;760.</Citation></Reference><Reference><Citation>Rickles AS, Dietz DW, Chang GJ, et al.; Consortium for Optimizing the Treatment of Rectal Cancer (OSTRiCh). High rate of positive circumferential resection margins following rectal cancer surgery: a call to action. Ann Surg. 2015;262:891&#x2013;898.</Citation></Reference><Reference><Citation>Simon HL, de Paula TR, Profeta da Luz MM, Kiran RP, Keller DS. Predictors of positive circumferential resection margin in rectal cancer: a current audit of the National Cancer Database. Dis Colon Rectum. 2021;64:1096&#x2013;1105.</Citation></Reference><Reference><Citation>Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet. 2000;356:93&#x2013;96.</Citation></Reference><Reference><Citation>Carlsen E, Schlichting E, Guldvog I, Johnson E, Heald RJ. Effect of the introduction of total mesorectal excision for the treatment of rectal cancer. Br J Surg. 1998;85:526&#x2013;529.</Citation></Reference><Reference><Citation>Wexner SD, Berho ME. The rationale for and reality of the new national accreditation program for rectal cancer. Dis Colon Rectum. 2017;60:595&#x2013;602.</Citation></Reference><Reference><Citation>Marks J, Saidi H, Reif de Paula T, Ikner T, Schoonyoung H, Keller DS. Longitudinal analysis of local recurrence and survival after transanal radical proctosigmoidectomy (TATA) for low rectal cancer [ASCRS abstract M12]. Dis Colon Rectum. 2023;66:e378&#x2013;e379.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36876985</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Oncological Outcomes of Transanal Endoscopic Surgery for the Surgical Management of T2 and T3 Rectal Cancer.</ArticleTitle><Pagination><StartPage>1012</StartPage><EndPage>1021</EndPage><MedlinePgn>1012-1021</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002617</ELocationID><Abstract><AbstractText Label="BACKGROUND">Transanal endoscopic surgery is an organ-sparing treatment for early rectal cancer. Patients with advanced lesions are recommended for total mesorectal excision. However, some patients have prohibitive comorbidities or refuse major surgery.</AbstractText><AbstractText Label="OBJECTIVE">To assess the cancer outcomes of patients with T2 or T3 rectal cancers who received transanal endoscopic surgery as their sole surgical treatment.</AbstractText><AbstractText Label="DESIGN">This study used a prospectively maintained database.</AbstractText><AbstractText Label="SETTING">A tertiary hospital in Canada.</AbstractText><AbstractText Label="PATIENTS">Patients who underwent transanal endoscopic surgery for pathology-confirmed T2 or T3 rectal adenocarcinomas from 2007-2020 were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Disease-free survival and overall survival, stratified by tumor stage and reason for transanal endoscopic surgery.</AbstractText><AbstractText Label="RESULTS">Among the included 132 patients (T2, n = 96; T3, n = 36), average follow-up was 22 months. Twenty-eight decline oncologic resection, whereas 104 had preclusive comorbidities. Fifteen patients (11.4%) had disease recurrence (4 local, 11 metastatic). Three-year disease-free survival was 86.5% (95% CI, 77.1-95.9) for T2 and 67.9% (95% CI, 46.3-89.5) for T3 tumors. Mean disease-free survival was longer for T2 (75.0 mo; 95% CI, 67.8-82.1) compared to T3 cancers (50 mo; 95% CI, 37.7-62.3; p = 0.037). Three-year disease-free survival for patients who declined radical excision was 84.0% (95% CI, 67.1-100) versus 80.7% (95% CI, 69.7-91.7) in patients too comorbid for surgery. Three-year overall survival rate was 84.9% (95% CI, 73.9-95.9) for T2 and 49.0% (95% CI, 26.7-71.3) for T3 tumors. Patients who declined radical resection had similar 3-year overall survival (89.7%; 95% CI, 76.2-100) compared to patients who were unable to undergo excision because of medical comorbidities (98.1%; 95% CI, 95.6-100).</AbstractText><AbstractText Label="LIMITATIONS">Small sample, single institution, and surgeon experience.</AbstractText><AbstractText Label="CONCLUSIONS">Oncologic outcomes are compromised in patients treated by transanal endoscopic surgery for T2 and T3 rectal cancer. Transanal endoscopic surgery remains an option for informed patients who prefer to avoid radical resection. See Video Abstract at http://links.lww.com/DCR/C200 .</AbstractText><AbstractText Label="RESULTADOS ONCOLGICOS DE LA CIRUGA ENDOSCPICA TRANSANAL PARA EL MANEJO QUIRRGICO DEL CNCER DE RECTO T Y T">ANTECEDENTES:La cirug&#xed;a endosc&#xf3;pica transanal es un tratamiento de conservaci&#xf3;n de &#xf3;rganos para el c&#xe1;ncer de recto en estadio temprano. A los pacisentes con lesiones avanzadas se les recomienda la escisi&#xf3;n total del mesorrecto. Sin embargo, algunos pacientes tienen comorbilidades prohibitivas o rechazan una cirug&#xed;a mayor.OBJETIVO:Evaluar los resultados del c&#xe1;ncer de pacientes con c&#xe1;ncer de recto T2 o T3 que recibieron cirug&#xed;a endosc&#xf3;pica transanal como &#xfa;nico tratamiento quir&#xfa;rgico.DISE&#xd1;O:Este estudio utiliz&#xf3; una base de datos mantenida prospectivamente.ENTORNO CLINICO:Un hospital terciario en Canad&#xe1;PACIENTES:Aquellos que se sometieron a cirug&#xed;a endosc&#xf3;pica transanal por adenocarcinomas rectales T2 o T3 confirmados por patolog&#xed;a de 2007-2020. Se excluyeron los pacientes cuya cirug&#xed;a se realiz&#xf3; por recurrencia del c&#xe1;ncer o posteriormente fueron sometidos a resecci&#xf3;n radical.PRINCIPALES MEDIDAS DE VALORACI&#xd3;N:Supervivencia libre de enfermedad y supervivencia global, estratificada por estadio del tumor y motivo de la cirug&#xed;a endosc&#xf3;pica transanal.RESULTADOS:Se incluyeron 132 pacientes (T2, n = 96; T3, n = 36). El seguimiento medio fue de 22 meses (DE &#xb1; 23,4). 104 pacientes ten&#xed;an comorbilidades significativas, mientras que 28 rechazaron la resecci&#xf3;n oncol&#xf3;gica. Quince pacientes (11,4%) tuvieron recurrencia de la enfermedad (4 locales, 11 metast&#xe1;sicos). La supervivencia libre de enfermedad a los tres a&#xf1;os para los tumores T2 fue del 86,5 % (IC del 95%: 77,1-95,9) y del 67,9% (IC del 95%: 46,3-89,5) para los tumores T3. La supervivencia libre de enfermedad media fue m&#xe1;s prolongada para los c&#xe1;nceres T2 (75,0 meses, IC del 95%: 67,8 a 82,1) en comparaci&#xf3;n con los c&#xe1;nceres T3 (50 meses, IC del 95%: 37,7 a 62,3, p = 0,037). La supervivencia sin enfermedad a los tres a&#xf1;os para los pacientes que rechazaron la escisi&#xf3;n mesorrectal total fue del 84,0% (IC del 95%: 67,1-100), mientras que los pacientes con demasiada comorbilidad m&#xe9;dica para la cirug&#xed;a tuvieron una supervivencia sin enfermedad a los tres a&#xf1;os del 80,7% (IC del 95%: 69.7-91.7). La supervivencia general a los tres a&#xf1;os fue del 84,9% (IC del 95%: 73,9 a 95,9) para los tumores T2 y del 49,0% (IC del 95%: 26,7 a 71,3) para los tumores T3. Los pacientes que rechazaron la resecci&#xf3;n radical tuvieron una supervivencia general similar a los tres a&#xf1;os (89,7%, IC del 95%: 76,2-100), en comparaci&#xf3;n con los pacientes que no pudieron someterse a una escisi&#xf3;n mesorrectal total debido a comorbilidades m&#xe9;dicas (98,1%, IC del 95%: 95,6-100).LIMITACIONES:Muestra peque&#xf1;a, instituci&#xf3;n &#xfa;nica, experiencia del cirujano.CONCLUSIONES:Los resultados oncol&#xf3;gicos est&#xe1;n comprometidos en pacientes tratados con cirug&#xed;a endosc&#xf3;pica transanal por c&#xe1;ncer de recto T2 y T3. Sin embargo, la cirug&#xed;a endosc&#xf3;pica transanal sigue siendo una opci&#xf3;n para pacientes informados que prefieren evitar la resecci&#xf3;n radical. Consulte Video Resumen en http://links.lww.com/DCR/C200 . (Traducci&#xf3;n-Dr. Ingrid Melo ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Garrett G R J</ForeName><Initials>GGRJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>Reagan L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Vergis</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Raval</LastName><ForeName>Manoj</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Phang</LastName><ForeName>Terry</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Karimuddin</LastName><ForeName>Ahmer</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067368" MajorTopicYN="Y">Transanal Endoscopic Surgery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>6</Day><Hour>8</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36876985</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002617</ArticleId><ArticleId IdType="pii">00003453-202307000-00021</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heidary B, Phang TP, Raval MJ, Brown CJ. Transanal endoscopic microsurgery: a review. Can J Surg. 2014;57:127&#x2013;138.</Citation></Reference><Reference><Citation>Guerrieri M, Baldarelli M, Morino M, et al. Transanal endoscopic microsurgery in rectal adenomas: experience of six Italian centres. Dig Endosc. 2006;38:P202&#x2013;P207.</Citation></Reference><Reference><Citation>Guerrieri M, Gesuita R, Ghiselli R, Lezoche G, Budassi A, Baldarelli M. Treatment of rectal cancer by transanal endoscopic microsurgery: experience with 425 patients. World J Gastroenterol. 2014;20:9556&#x2013;9563.</Citation></Reference><Reference><Citation>D&#x2019;Ambrosio G, Paganini AM, Balla A, et al. Quality of life in non-early rectal cancer treated by neoadjuvant radio-chemotherapy and endoluminal loco-regional resection (ELRR) by transanal endoscopic microsurgery (TEM) versus laparoscopic total mesorectal excision. Surg Endosc. 2016;30:504&#x2013;511.</Citation></Reference><Reference><Citation>Dias AR, Nahas CSR, Marques CFS, Nahas SC, Cecconello I. Transanal endoscopic microsurgery: indications, results and controversies. Tech Coloproctol. 2009;13:105&#x2013;111.</Citation></Reference><Reference><Citation>Bach SP, Hill J, Monson JRT, et al.; Association of Coloproctology of Great Britain and Ireland Transanal Endoscopic Microsurgery (TEM) Collaboration. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg. 2009;96:280&#x2013;290.</Citation></Reference><Reference><Citation>Lee W, Lee D, Choi S, Chun H. Transanal endoscopic microsurgery and radical surgery for T1 and T2 rectal cancer. Surg Endosc. 2003;17:1283&#x2013;1287.</Citation></Reference><Reference><Citation>Stijns RCH, de Graaf EJR, Punt CJA, et al.; CARTS Study Group. Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer: the CARTS study. JAMA Surg. 2019;154:47&#x2013;54.</Citation></Reference><Reference><Citation>Ali F, Keshinro A, Weiser MR. Advances in the treatment of locally advanced rectal cancer. Ann Gastroenterol Surg. 2020;5:32&#x2013;38.</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453&#x2013;1457.</Citation></Reference><Reference><Citation>Ramkumar J, Letarte F, Karimuddin AA, Phang PT, Raval MJ, Brown CJ. Assessing the safety and outcomes of repeat transanal endoscopic microsurgery. Surg Endosc. 2019;33:1976&#x2013;1980.</Citation></Reference><Reference><Citation>Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457&#x2013;481.</Citation></Reference><Reference><Citation>Fields AC, Lu PW, Yoo J, et al. Treatment of stage I-III rectal cancer: who is refusing surgery? J Surg Oncol. 2020;121:990&#x2013;1000.</Citation></Reference><Reference><Citation>Bethune R, Sbaih M, Brosnan C, Arulampalam T. What happens when we do not operate? Survival following conservative bowel cancer management. Ann R Coll Surg Engl. 2016;98:409&#x2013;412.</Citation></Reference><Reference><Citation>Keshava HB, Rosen JE, DeLuzio MR, Kim AW, Detterbeck FC, Boffa DJ. &#x201c;What if I do nothing?&#x201d; The natural history of operable cancer of the alimentary tract. Eur J Surg Oncol. 2017;43:788&#x2013;795.</Citation></Reference><Reference><Citation>Rullier E, Rouanet P, Tuech JJ, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet. 2017;390:469&#x2013;479.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, Renfro LA, Chow OS, et al. Organ presevation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision: results of a multicenter phase 2 study. Lancet Oncol. 2015;16:1537&#x2013;1546.</Citation></Reference><Reference><Citation>Serra-Aracil X, Pericay C, Golda T, et al.; TAU-TEM study group. Non-inferiority multicenter prospective randomized controlled study of rectal cancer T 2 -T 3s (superficial) N 0 , M 0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME). Int J Colorectal Dis. 2018;33:241&#x2013;249.</Citation></Reference><Reference><Citation>Bach SP, Gilbert A, Brock K, et al.; TREC collaborators. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. Lancet Gastroenterol Hepatol. 2021;6:92&#x2013;105.</Citation></Reference><Reference><Citation>Verseveld M, de Graaf EJR, Verhoef C, et al.; CARTS Study Group. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg. 2015;102:853&#x2013;860.</Citation></Reference><Reference><Citation>Xu ZS, Cheng H, Xiao Y, et al. Comparison of transanal endoscopic microsurgery with or without neoadjuvant therapy and standard total mesorectal excision in the treatment of clinical T2 low rectal cancer: a meta-analysis. Oncotarget. 2017;8:115681&#x2013;115690.</Citation></Reference><Reference><Citation>Jawitz OK, Adam MA, Turner MC, Gilmore BF, Migaly J. Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection. Surgery. 2019;165:1193&#x2013;1198.</Citation></Reference><Reference><Citation>Leijtens JWA, Koedam TWA, Borstlap WAA, et al. Transanal endoscopic microsurgery with or without completion total mesorectal excision for T2 and T3 rectal carcinoma. Dig Surg. 2019;36:76&#x2013;82.</Citation></Reference><Reference><Citation>Heintz A, M&#xf6;rschel M, Junginger T. Comparison of results after transanal endoscopic microsurgery and radical resection for T1 carcinoma of the rectum. Surg Endosc. 1998;12:1145&#x2013;1148.</Citation></Reference><Reference><Citation>Batra A, Kong S, Cheung WY. Eligibility of real-world patients with stage II and III colon cancer for adjuvant chemotherapy trials. Clin Colorectal Cancer. 2020;19:e226&#x2013;e234.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, Patil S, Kim JK, et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. JCO. 2020;38(suppl):4008&#x2013;4008.</Citation></Reference><Reference><Citation>NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines): rectal cancer (version 1.2022). Published February 25, 2022. https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1461 . Accessed May 30, 2022.</Citation></Reference><Reference><Citation>Rullier E, Vendrely V, Asselineau J, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 2020;5:465&#x2013;474.</Citation></Reference><Reference><Citation>Xu K, Liu Y, Yu P, et al. Oncological outcomes of transanal endoscopic microsurgery plus adjuvant chemoradiotherapy for patients with high-risk T1 and T2 rectal cancer. J Laparoendosc Adv Surg Tech A. 2021;31:1006&#x2013;1013.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36649177</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Does Completeness of the Mesorectal Excision Still Correlate With Local Recurrence?</ArticleTitle><Pagination><StartPage>898</StartPage><EndPage>904</EndPage><MedlinePgn>898-904</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002551</ELocationID><Abstract><AbstractText Label="BACKGROUND">Total mesorectal excision is the standard surgical procedure for rectal cancer treatment. Several studies have shown a close correlation between the prognosis of patients with rectal cancer and the completeness of the mesorectal specimen.</AbstractText><AbstractText Label="OBJECTIVE">To assess the correlation between macroscopic assessment of mesorectal excision and long-term oncological outcomes.</AbstractText><AbstractText Label="DESIGN">Retrospective analysis of an Institutional Review Board-approved database.</AbstractText><AbstractText Label="SETTINGS">Tertiary referral center.</AbstractText><AbstractText Label="PATIENTS">Patients with rectal cancer who were operated on between March 2016 and October 2019 were classified into 3 groups based on the mesorectal specimen quality: complete, near complete, and incomplete. Only patients with a follow-up of &#x2265;2 years and without signs of preoperative distant disease were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Relationship between total mesorectal excision and local and distant recurrence rates in patients with rectal cancer.</AbstractText><AbstractText Label="RESULTS">A total of 124 patients (35.5% females) were included in the analysis, with a mean age of 58.1 (SD 12) years and a mean BMI of 26.4 (SD 4.59) kg/m&#xb2;. Neoadjuvant chemoradiation was administered to 71% of patients, whereas 13.7% received total neoadjuvant therapy. Restorative procedures were performed in 107 patients (86.3%), whereas 17 patients (13.7%) underwent abdominoperineal resection. The majority of mesorectal excision specimens (87.09%) were complete or near complete. Local recurrence rates were 6.3% (1/16) in the incomplete and 7.4% (8/108) in the complete/near complete group ( p = 0.86). Metachronous distant metastases occurred in 6 patients (37.5%) in the incomplete group and in 24 patients (22.2%) in the complete/near complete group (p = 0.18). Thus, specimen quality did not appear to impact disease-free survival.</AbstractText><AbstractText Label="LIMITATIONS">Retrospective, single-center study with relatively short follow-up.</AbstractText><AbstractText Label="CONCLUSIONS">In the era of a multidisciplinary approach and extensive use of neoadjuvant therapy, macroscopic completeness of total mesorectal excision may not be as valuable a prognosticator as in the past. Larger studies with longer follow-ups are needed to clarify these preliminary findings. See Video Abstract at http://links.lww.com/DCR/C129.</AbstractText><AbstractText Label="LA INTEGRIDAD DE LA ESCISIN MESORRECTAL TODAVA SE CORRELACIONA CON LA RECURRENCIA LOCAL">ANTECEDENTES:La escisi&#xf3;n total desl mesorrecto es el est&#xe1;ndar de oro para el tratamiento del c&#xe1;ncer de recto. Varios estudios han demostrado una estrecha correlaci&#xf3;n entre el pron&#xf3;stico de los pacientes con c&#xe1;ncer de recto y la integridad esp&#xe9;cimen mesorrectal.OBJETIVO:Evaluar la correlaci&#xf3;n entre la evaluaci&#xf3;n macrosc&#xf3;pica de la escisi&#xf3;n mesorrectal y los resultados oncol&#xf3;gicos a largo plazo en pacientes con c&#xe1;ncer de recto.DISE&#xd1;O:An&#xe1;lisis retrospectivo de una base de datos aprobada por el IRB.ENTORNO CLINICO:El estudio se realiz&#xf3; en un centro de referencia terciario de una sola instituci&#xf3;n.PACIENTES:Todos los pacientes con c&#xe1;ncer de recto operados entre 3/2016-10/2019. Los pacientes se clasificaron en 3 grupos, seg&#xfa;n la calidad del esp&#xe9;cimen mesorrectal: completo, casi completo e incompleto. Solo se incluyeron pacientes con seguimiento &gt;2 a&#xf1;os y sin signos de enfermedad a distancia preoperatoria.PRINCIPALES MEDIDAS DE RESULTADO:Identificar la relaci&#xf3;n entre la escisi&#xf3;n mesorrectal total y las tasas de recurrencia local y a distancia en pacientes con c&#xe1;ncer de recto.RESULTADOS:Se incluyeron 124 pacientes (35,5% mujeres) con una edad media de 58,1 a&#xf1;os (DE 12) y un &#xed;ndice de masa corporal medio de 26,4 (DE 4,59). Se administr&#xf3; quimiorradiaci&#xf3;n neoadyuvante al 71% de los pacientes, mientras que el 13,7% recibi&#xf3; terapia neoadyuvante total. Se realizaron procedimientos de restauraci&#xf3;n en 107 pacientes (86,3%), mientras que 17 pacientes (13,7%) se sometieron a resecci&#xf3;n abdominoperineal. La mayor&#xed;a (87,09%) de los espec&#xed;menes de escisi&#xf3;n mesorrectal fueron completas o casi completas. Las tasas de recurrencia local fueron 1/16 (6,3%) en el grupo incompleto y 8/108 (7,4%) en el grupo completo/casi completo ( p = 0,86). Se produjeron met&#xe1;stasis a distancia metacr&#xf3;nicas en 6 pacientes (37,5%) en el grupo incompleto y 24 (22,2%) en el grupo completo/casi completo ( p = 0,18). Por lo tanto, la calidad del esp&#xe9;cimen no pareci&#xf3; afectar la supervivencia libre de enfermedad.LIMITACIONES:Estudio retrospectivo de un solo centro con peque&#xf1;o n&#xfa;mero de casos y seguimiento relativamente corto.CONCLUSI&#xd3;N:En la era de un enfoque multidisciplinario y el uso extensivo de la terapia neoadyuvante, la integridad macrosc&#xf3;pica de la escisi&#xf3;n total del mesorrecto, puede no ser un pron&#xf3;stico tan valioso como en el pasado. Se necesitan estudios m&#xe1;s amplios con per&#xed;odos de seguimiento m&#xe1;s prolongados para aclarar estos hallazgos preliminares. Consulte Video Resumen en http://links.lww.com/DCR/C129 . (Traducci&#xf3;n-Dr. Fidel Ruiz Healy ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garoufalia</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freund</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gefen</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Faculty of Medicine, Hadassah Medical Organization, Hebrew University of Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DaSilva</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Eric G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wexner</LastName><ForeName>Steven D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012007" MajorTopicYN="Y">Rectum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>17</Day><Hour>12</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36649177</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002551</ArticleId><ArticleId IdType="pii">00003453-202307000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1:1479&#x2013;1482.</Citation></Reference><Reference><Citation>Bosch SL, Nagtegaal ID. The importance of the pathologist&#x2019;s role in assessment of the quality of the mesorectum. Curr Colorectal Cancer Rep. 2012;8:90&#x2013;98.</Citation></Reference><Reference><Citation>Quirke P, Steele R, Monson J, et al.; MRC CR07/NCIC-CTG CO16 Trial Investigators; NCRI Colorectal Cancer Study Group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373:821&#x2013;828.</Citation></Reference><Reference><Citation>Nagtegaal ID, van de Velde CJ, van der WorpKapiteijn E, et al.; Cooperative Clinical Investigators of the Dutch Colorectal Cancer Group. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol. 2002;20:1729&#x2013;1734.</Citation></Reference><Reference><Citation>Nagtegaal ID, van Krieken JH. The multidisciplinary treatment of rectal cancer: pathology. Ann Oncol. 2007;18:ix122&#x2013;ix126.</Citation></Reference><Reference><Citation>Jeyarajah S, Sutton CD, Miller AS, Hemingway D; Leicester Colorectal Specialist Group. Factors that influence the adequacy of total mesorectal excision for rectal cancer. Colorectal Dis. 2007;9:808&#x2013;815.</Citation></Reference><Reference><Citation>Leonard D, Penninckx F, Laenen A, Kartheuser A; PROCARE. Scoring the quality of total mesorectal excision for the prediction of cancer-specific outcome. Colorectal Dis. 2015;17:O115&#x2013;O122.</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453&#x2013;1457.</Citation></Reference><Reference><Citation>Hermanek P, Hermanek P, Hohenberger W, Klimpfinger M, K&#xf6;ckerling F, Papadopoulos T. The pathological assessment of mesorectal excision: implications for further treatment and quality management. Int J Colorectal Dis. 2003;18:335&#x2013;341.</Citation></Reference><Reference><Citation>Garc&#xed;a-Granero E, Faiz O, Mu&#xf1;oz E, et al. Macroscopic assessment of mesorectal excision in rectal cancer: a useful tool for improving quality control in a multidisciplinary team. Cancer. 2009;115:3400&#x2013;3411.</Citation></Reference><Reference><Citation>Heald RJ, Husband EM, Ryall RDH. The mesorectum in rectal cancer surgery&#x2014;the clue to pelvic recurrence? Br J Surg. 1982;69:613&#x2013;616.</Citation></Reference><Reference><Citation>Knol J, Keller DS. Total mesorectal excision technique-past, present, and future. Clin Colon Rectal Surg. 2020;33:134&#x2013;143.</Citation></Reference><Reference><Citation>van Lingen CP, Zeebregts CJ, Gerritsen JJ, Mulder HJ, Mastboom WJ, Klaase JM. Local recurrence of rectal cancer after total mesorectal excision without preoperative radiotherapy. Int J Gastrointest Cancer. 2003;34:129&#x2013;134.</Citation></Reference><Reference><Citation>B&#xfc;low S, Christensen IJ, Harling H, Kronborg O, Fenger C, Nielsen HJ; Danish TME Study Group; RANX05 Colorectal Cancer Study Group. Recurrence and survival after mesorectal excision for rectal cancer. Br J Surg. 2003;90:974&#x2013;980.</Citation></Reference><Reference><Citation>van Gijn W, Marijnen CAM, Nagtegaal ID, et al.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575&#x2013;582.</Citation></Reference><Reference><Citation>Maslekar S, Sharma A, Macdonald A, Gunn J, Monson JR, Hartley JE. Mesorectal grades predict recurrences after curative resection for rectal cancer. Dis Colon Rectum. 2007;50:168&#x2013;175.</Citation></Reference><Reference><Citation>Kitz J, Fokas E, Beissbarth T, et al.; German Rectal Cancer Study Group. Association of plane of total mesorectal excision with prognosis of rectal cancer: secondary analysis of the CAO/ARO/AIO-04 phase 3 randomized clinical trial. JAMA Surg. 2018;153:e181607.</Citation></Reference><Reference><Citation>NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444&#x2013;1450.</Citation></Reference><Reference><Citation>MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457&#x2013;460.</Citation></Reference><Reference><Citation>Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638&#x2013;646.</Citation></Reference><Reference><Citation>Marsh PJ, James RD, Schofield PF. Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma. Results of a prospective, randomized trial. Dis Colon Rectum. 1994;37:1205&#x2013;1214.</Citation></Reference><Reference><Citation>Martling A, Holm T, Rutqvist LE, et al. Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg. 2005;92:225&#x2013;229.</Citation></Reference><Reference><Citation>Cedermark B, Dahlberg M, Glimelius B, P&#xe5;hlman L, Rutqvist LE, Wilking N; Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980&#x2013;987.</Citation></Reference><Reference><Citation>Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811&#x2013;820.</Citation></Reference><Reference><Citation>Bosset JF, Collette L, Calais G, et al.; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114&#x2013;1123.</Citation></Reference><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7&#x2013;30.</Citation></Reference><Reference><Citation>Bosset JF, Calais G, Mineur L, et al.; EORTC Radiation Oncology Group. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184&#x2013;190.</Citation></Reference><Reference><Citation>Sainato A, Cernusco Luna Nunzia V, Valentini V, et al. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113:223&#x2013;229.</Citation></Reference><Reference><Citation>Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol. 2006;24:668&#x2013;674.</Citation></Reference><Reference><Citation>Kasi A, Abbasi S, Handa S, et al. Total Neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3:e2030097.</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network. Rectal cancer (Version 2.2021 &#x2013; September 10, 2021). https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1461 . Accessed 26, November 2021.</Citation></Reference><Reference><Citation>Glynne-Jones R, Wyrwicz L, Tiret E, et al.; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22&#x2013;iv40.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36538720</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Impact of Total Neoadjuvant Therapy on Postoperative Outcomes After Proctectomy for Rectal Cancer.</ArticleTitle><Pagination><StartPage>1022</StartPage><EndPage>1028</EndPage><MedlinePgn>1022-1028</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002555</ELocationID><Abstract><AbstractText Label="BACKGROUND">Total neoadjuvant therapy is an alternative to neoadjuvant chemoradiation alone for rectal cancer and has the benefits of more completion of planned therapy, increased downstaging, earlier treatment of micrometastases, and assessment of chemosensitivity; however, it may increase surgical complications, especially with increased radiation-to-surgery interval.</AbstractText><AbstractText Label="OBJECTIVE">The study aimed to determine the impact of total neoadjuvant therapy on postoperative complications compared with neoadjuvant chemoradiation alone.</AbstractText><AbstractText Label="DESIGN">Retrospective cohort study.</AbstractText><AbstractText Label="SETTINGS">Single tertiary referral center.</AbstractText><AbstractText Label="PATIENTS">The patient included was a stage II/III rectal cancer patient who underwent total neoadjuvant therapy or long-course neoadjuvant chemoradiation followed by surgical resection from 2018-2020.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The main outcome measures included severe postoperative complications (Clavien-Dindo grade &#x2265;3).</AbstractText><AbstractText Label="RESULTS">Of 181 patients, 86 (47.5%) underwent total neoadjuvant therapy and 95 (52.5%) underwent neoadjuvant chemoradiation. There was no difference in severe postoperative complications or any complications. There was also no difference in the rate of complete total mesorectal excision or negative circumferential margin. Total neoadjuvant therapy had a mean operative time of 355.5 minutes and estimated blood loss of 263.6&#x2009;mL compared with 326.7 minutes and 297.5&#x2009;mL in the neoadjuvant chemoradiation group. Total neoadjuvant therapy patients had a lower mean lymph node yield than neoadjuvant chemoradiation patients. On multivariable analysis, total neoadjuvant therapy was associated with increased operative time (OR, 1.19; p &lt; 0.001) and estimated blood loss (OR, 1.22; p &lt; 0.001) and decreased lymph node yield (OR, 0.67; p &lt; 0.001). There was no difference in severe complications or any complications.</AbstractText><AbstractText Label="LIMITATIONS">Selection bias uncontrolled by modeling.</AbstractText><AbstractText Label="CONCLUSIONS">We found no difference in risk of postoperative complications between patients who received total neoadjuvant therapy vs neoadjuvant chemoradiation. Total neoadjuvant therapy patients had longer operations and greater estimated blood loss. This may be a reflection of increased operative difficulty because of increased radiation-to-surgery interval and/or the effects of chemotherapy; however, the absolute differences were small and, therefore, should be interpreted cautiously. See Video Abstract at http://links.lww.com/DCR/C44 .</AbstractText><AbstractText Label="IMPACTO DE LA TERAPIA NEOADYUVANTE TOTAL EN LOS RESULTADOS POSOPERATORIOS DESPUS DE UNA PROCTECTOMA POR CNCER DE RECTO">ANTECEDENTES:La terapia neoadyuvante total es una alternativa a la quimiorradiaci&#xf3;n neoadyuvante sola para el c&#xe1;ncer de recto y tiene los beneficios de una mayor finalizaci&#xf3;n de la terapia planificada, mayor reducci&#xf3;n del estadiage, tratamiento m&#xe1;s temprano de las micromet&#xe1;stasis y evaluaci&#xf3;n de la quimiosensibilidad; sin embargo, puede aumentar las complicaciones quir&#xfa;rgicas, especialmente con un mayor intervalo entre la radiaci&#xf3;n y la cirug&#xed;a.OBJETIVO:Determinar el impacto de la terapia neoadyuvante total sobre las complicaciones posoperatorias en comparaci&#xf3;n con la quimiorradiaci&#xf3;n neoadyuvante sola.DISE&#xd1;O:Estudio de cohorte retrospectivo.ENTORNO CLINICO:Centro &#xfa;nico de referencia terciario.PACIENTES:Paciente con c&#xe1;ncer de recto en estadio II/III que se sometieron a terapia neoadyuvante total o quimiorradiaci&#xf3;n neoadyuvante de larga duraci&#xf3;n seguida de resecci&#xf3;n quir&#xfa;rgica entre 2018 y 2020.PRINCIPALES MEDIDAS DE RESULTADO:Complicaciones postoperatorias graves (grado de Clavien-Dindo &#x2265;3).RESULTADOS:De 181 pacientes, 86 (47,5%) se sometieron a terapia neoadyuvante total y 95 (52,5%) se sometieron a quimiorradioterapia neoadyuvante. No hubo diferencia en las complicaciones postoperatorias graves o cualquier otra complicaci&#xf3;n. Tampoco hubo diferencia en la tasa de escisi&#xf3;n mesorrectal total completa o margen circunferencial negativo. La terapia neoadyuvante total tuvo un tiempo operatorio promedio de 355,5 minutos y una p&#xe9;rdida de sangre estimada de 263,6&#x2009;ml en comparaci&#xf3;n con 326,7 minutos y 297,5&#x2009;ml en el grupo de quimiorradiaci&#xf3;n neoadyuvante. Los pacientes con terapia neoadyuvante total tuvieron una media de ganglios linf&#xe1;ticos m&#xe1;s bajo en comparaci&#xf3;n con los pacientes con quimiorradioterapia neoadyuvante. En el an&#xe1;lisis multivariable, la terapia neoadyuvante total se asoci&#xf3; con un mayor tiempo operatorio (OR = 1,19, p &lt; 0,001) y p&#xe9;rdida de sangre estimada (OR = 1,22, p &lt; 0,001) y menor cantidad los ganglios linf&#xe1;ticos (OR = 0,67, p &lt; 0,001). No hubo diferencia en las complicaciones graves o cualquier complicaci&#xf3;n.LIMITACIONES:Sesgo de selecci&#xf3;n no controlado por modelado.CONCLUSIONES:No encontramos diferencias en el riesgo de complicaciones postoperatorias entre los pacientes que recibieron terapia neoadyuvante total versus quimiorradiaci&#xf3;n neoadyuvante. Los pacientes con terapia neoadyuvante total tuvieron operaciones m&#xe1;s prolongadas y una mayor p&#xe9;rdida de sangre estimada. Esto puede ser un reflejo de una mayor dificultad quir&#xfa;rgica como resultado de un mayor intervalo entre la radiaci&#xf3;n y la cirug&#xed;a y/o los efectos de la quimioterapia; sin embargo, las diferencias absolutas fueron peque&#xf1;as y, por lo tanto, deben interpretarse con cautela. Consulte Video Resumen en http://links.lww.com/DCR/C44 . (Traducci&#xf3;n- Dr. Francisco M. Abarca-Rendon ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhaomin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease &amp; Surgery Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Sklow</LastName><ForeName>Bradford</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Liska</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gorgun</LastName><ForeName>Emre</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kessler</LastName><ForeName>Hermann</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>David R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Steele</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="Y">Proctectomy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>20</Day><Hour>15</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36538720</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002555</ArticleId><ArticleId IdType="pii">00003453-202307000-00022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Gijn W, Marijnen CA, Nagtegaal ID, et al.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575&#x2013;582.</Citation></Reference><Reference><Citation>Cedermark B, Dahlberg M, Glimelius B, P&#xe5;hlman L, Rutqvist LE, Wilking N; Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980&#x2013;987.</Citation></Reference><Reference><Citation>Xu Z, Mohile SG, Tejani MA, et al. Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal cancer: an NCDB analysis. Cancer. 2017;123:52&#x2013;61.</Citation></Reference><Reference><Citation>Marco MR, Zhou L, Patil S, et al.; Timing of Rectal Cancer Response to Chemoradiation Consortium. Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis Colon Rectum. 2018;61:1146&#x2013;1155.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, Chow OS, Smith DD, et al.; Timing of Rectal Cancer Response to Chemoradiation Consortium. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16:957&#x2013;966.</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN guidelines): rectal cancer (version 2.2021). 2021. Accessed September 9, 2021. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf .</Citation></Reference><Reference><Citation>Marijnen CA, Kapiteijn E, van de Velde CJ, et al.; Cooperative Investigators of the Dutch Colorectal Cancer Group. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2002;20:817&#x2013;825.</Citation></Reference><Reference><Citation>Bauer PS, Chapman WC, Atallah C, et al. Perioperative complications after proctectomy for rectal cancer: does neoadjuvant regimen matter? Ann Surg. 2022;275:e428&#x2013;e432.</Citation></Reference><Reference><Citation>Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187&#x2013;196.</Citation></Reference><Reference><Citation>American College of Surgeons. Optimal resources for cancer care: 2020 standards. 2021. Accessed December 6, 2021. https://www.facs.org/-/media/files/quality-programs/cancer/coc/optimal_resources_for_cancer_care_2020_standards.ashx .</Citation></Reference><Reference><Citation>Burgart L, Kakar S, Shi C, et al. Protocol for the examination of resection specimens from patients with primary carcinoma of the colon and rectum. 2020. Accessed September 30, 2021. https://documents.cap.org/protocols/cp-gilower-colonrectum-resection-20-4100.pdf .</Citation></Reference><Reference><Citation>Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34:3773&#x2013;3780.</Citation></Reference><Reference><Citation>Ripoll&#xe9;s-Melchor J, Ram&#xed;rez-Rodr&#xed;guez JM, Casans-Franc&#xe9;s R, et al.; POWER Study Investigators Group for the Spanish Perioperative Audit and Research Network (REDGERM). Association between use of enhanced recovery after surgery protocol and postoperative complications in colorectal surgery: the postoperative outcomes within enhanced recovery after surgery protocol (POWER) study. JAMA Surg. 2019;154:725&#x2013;736.</Citation></Reference><Reference><Citation>Erlandsson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18:336&#x2013;346.</Citation></Reference><Reference><Citation>Jagie&#x142;a J, Bartnicki P, Rysz J. Nephrotoxicity as a complication of chemotherapy and immunotherapy in the treatment of colorectal cancer, melanoma and non-small cell lung cancer. Int J Mol Sci. 2021;22:4618.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM; Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011;254:97&#x2013;102.</Citation></Reference><Reference><Citation>Sermier A, Gervaz P, Egger JF, et al. Lymph node retrieval in abdominoperineal surgical specimen is radiation time-dependent. World J Surg Oncol. 2006;4:29.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>